On December 18, 2023, the Minister of Health announced the creation of the Canadian Drug Agency. According to the announcement, the Canadian Drug Agency (CDA) “will provide the dedicated leadership and coordination needed to make Canada's drug system more sustainable and better prepared for the future, helping Canadians achieve better health outcomes.” It will be built from the Canadian Agency for Drugs and Technologies in Health (CADTH), in partnership with provinces and territories. The CDA will build on CADTH’s mandate and functions, and will expand them, including improving appropriate prescribing and use of medications, and increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency seeks input on HTA methods guide and also announces new coalition to improve medication use
HTA Methods Guide – On November 28, 2024, Canada’s Drug Agency (CDA) launched a consultation on its first-ever methods guide.Read More -
2023-2024 Pan-Canadian Pharmaceutical Alliance impact report
On November 22, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) released its 2023-2024 impact report.Read More -
PMPRB releases new Draft Guidelines for comment
Following its Phase 2 Consultations, on December 19, 2025, the Patented Medicine Prices Review Board released its new Draft Guidelines and accompanying Overview.Read More